AbbVie vs J&J Dividend Kings Showdown | Business and Finance News

Two Dividend Kings, AbbVie and Johnson & Johnson, are reshaping their futures—AbbVie’s $10.9B Apogee acquisition targets eczema breakthroughs, while J&J focuses on pharma and devices after spinning off consumer goods. Both boast decades of dividend growth, but AbbVie’s 17% annual gains and lower valuation edge it over J&J’s 9% returns and steeper price tag. Neither is a bargain now, but AbbVie offers a slightly better value and yield. Watch for emerging stocks analysts say could outperform. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/f8e277728b3c1617